. Author manuscript; available in PMC: 2013 Jun 1.

Published in final edited form as: Lancet Infect Dis. 2012 Mar 19;12(6):441–448. doi: 10.1016/S1473-3099(12)70037-3

Table 2.

Quarterly Study Drug Compliance Summary

	M1-M3	M4-M6	M6-M9	M9-M12	M12-M15	M15-M18	M18-M21	M21-M24
Acyclovir	93.8%	92.4%	94.0%	94.8%	94.2%	93.9%	95.4%	94.6%
Placebo	95.2%	92.0%	93.3%	94.6%	97.4%	96.4%	97.2%	96.9%
Completed visits	1299	1276	1088	1073	935	924	758	739
Missed Dispensing	4/1299 (0%)	39/1276 (3%)	30/1088 (3%)	23/1073 (2%)	14/935 (1%)	17/924 (2%)	8/758 (1%)	10/739 (1%)

* This table includes scheduled monthly study drug dispensing visits for uncensored subjects and subjects not yet meeting an endpoint for the primary analysis.